Component
Stroke-like episode frequency in the taurine MELAS trial
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
During the ten-patient 52-week open-label MELAS trial, six patients had no stroke-like episodes in the evaluation period and annual episode frequency fell from 2.22 to 0.72.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_access
- Primary abstract
- experimental_model
- Within-patient comparison without a placebo group.
- limitations
- The 60% response estimate had a wide 95% CI of 26.2–87.8%; no general anti-aging or energy inference.
- nutrient_topic
- Taurine collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Taurine
- plain_language
- The small disease-specific study reported fewer episodes during treatment.
- primary_references
- Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. · 2019 · https://pubmed.ncbi.nlm.nih.gov/29666206/ · DOI 10.1136/jnnp-2018-317964
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Taurine: synthesis, transport, mitochondrial decoding and nutrient interactions (2026-09-19) · lines 289–295
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Within-patient comparison without a placebo group. · source_derived_draft · unverified_draft
## taurine-melas-episodes The small disease-specific study reported fewer episodes during treatment. During the ten-patient 52-week open-label MELAS trial, six patients had no stroke-like episodes in the evaluation period and annual episode frequency fell from 2.22 to 0.72. Model: Within-patient comparison without a placebo group. Limitations: The 60% response estimate had a wide 95% CI of 26.2–87.8%; no general anti-aging or energy inference. Evidence access: Primary abstract Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. · 2019 · https://pubmed.ncbi.nlm.nih.gov/29666206/ · DOI 10.1136/jnnp-2018-317964
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.